Article ID Journal Published Year Pages File Type
8485547 Vaccine 2018 11 Pages PDF
Abstract
As an alternative to producing recombinant protein, we engineered successfully the Nm-OM to express M2 Truncated-Nm-MIP, but lipooligosaccharide-extraction with Na-DOC was contra-indicated. Our data suggest that a multi-component vaccine containing a select number of Nm- and Ng-MIP type proteins would be required to provide broad coverage of both pathogens.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, ,